Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline Read more
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease Read more
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) Read more
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ, to the U.S. FDA Read more
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Read more
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs Read more
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Read more
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) Read more